Naratriptan and Gastroesophageal reflux disease - a phase IV clinical study of FDA data

Summary:

Gastroesophageal reflux disease is reported as a side effect among people who take Naratriptan (naratriptan), especially for people who are female, 40-49 old, also take Ibuprofen, and have Multiple sclerosis relapse.

The phase IV clinical study analyzes which people have Gastroesophageal reflux disease when taking Naratriptan. It is created by eHealthMe based on reports of 1,407 people who have side effects when taking Naratriptan from the FDA, and is updated regularly.

What is Naratriptan?

Naratriptan has active ingredients of naratriptan. It is often used in migraine. eHealthMe is studying from 1,481 Naratriptan users. Check the latest studies of Naratriptan.

What is Gastroesophageal reflux disease?

Gastroesophageal reflux disease (a condition in which stomach contents leak backward from the stomach into the oesophagus) is found to be associated with 2,396 drugs and 3,490 conditions by eHealthMe. Check the latest studies of Gastroesophageal reflux disease.

On Jul, 13, 2026

1,407 people reported to have side effects when taking Naratriptan.
Among them, 21 people (1.49%) have Gastroesophageal reflux disease.

Could Naratriptan cause Gastroesophageal reflux disease?

Among these 21 people:

What is the gender of people who have Gastroesophageal reflux disease when taking Naratriptan? *

female: 100 %
male: 0.0 %

What is the age of people who have Gastroesophageal reflux disease when taking Naratriptan? *

What are other drugs people take besides Naratriptan? *

What are other side effects people have besides Gastroesophageal reflux disease? *

Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 9 people, 42.86%
Weakness: 7 people, 33.33%
Headache (pain in head): 7 people, 33.33%
Cough: 7 people, 33.33%
Fatigue (feeling of tiredness): 6 people, 28.57%
Vision Blurred: 6 people, 28.57%
Nausea (feeling of having an urge to vomit): 6 people, 28.57%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 6 people, 28.57%
White Blood Cell Count Decreased: 5 people, 23.81%
Laryngeal Oedema (swelling of larynx): 5 people, 23.81%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 5 people, 23.81%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 23.81%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 3 people, 14.29%
Pain: 3 people, 14.29%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 14.29%
Drowsiness: 3 people, 14.29%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 3 people, 14.29%
Type 2 Diabetes: 1 person, 4.76%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 4.76%
Neck Pain: 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Naratriptan and have Gastroesophageal reflux disease?

- Check whether Gastroesophageal reflux disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Naratriptan:

Naratriptan (1,481 reports)

Browse all side effects of Naratriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (2,396 drugs)

Browse all the conditions that are associated with Gastroesophageal reflux disease:

Gastroesophageal reflux disease (3,490 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on naratriptan (the active ingredients of Naratriptan) and Naratriptan (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.